What is OpenAI's new AI model for drug discovery called?

OpenAI's new AI model for drug discovery is called GPT-Rosalind.

Who are the early users of OpenAI's GPT-Rosalind model?

Early users of OpenAI's GPT-Rosalind model include Amgen Inc., Moderna Inc., and the Allen Institute.

What is the main purpose of OpenAI's GPT-Rosalind model?

The main purpose of OpenAI's GPT-Rosalind model is to accelerate drug discovery and help translate scientific studies into patient healthcare applications.

Home / Technology / AI Speeds Drug Discovery: OpenAI's New Model

AI Speeds Drug Discovery: OpenAI's New Model

17 Apr

•

Summary

OpenAI launches GPT-Rosalind for life sciences research.
Model aims to accelerate drug discovery and patient applications.
Early users include Amgen, Moderna, and Allen Institute.

AI Speeds Drug Discovery: OpenAI's New Model

OpenAI has launched an early version of an artificial intelligence model, GPT-Rosalind, designed to expedite drug discovery processes. This AI tool is specifically tailored for life sciences research, focusing on extracting insights from extensive data and converting scientific studies into practical healthcare solutions for patients. The model is being rolled out as a research preview to select business clients.

Notable early adopters of GPT-Rosalind include Amgen Inc., Moderna Inc., and the Allen Institute. These organizations will leverage the AI to assist in complex biological research, which increasingly relies on computational power. OpenAI anticipates that the model will act as a research partner, helping to streamline time-intensive aspects of scientific endeavors.